PRESS RELEASES & ARTICLES
STAY UPDATED

EMBL Ventures portfolio company Luxendo acquired by Bruker

May 08, 2017

Successful exit just 1.5 years after the Company’s founding proves investment rationale

PDF

Arsanis Completes $45.5 Million Series D Financing

April 26, 2017

Company set to advance pipeline of monoclonal antibodies for serious infectious diseases, including lead Phase 2 program ASN100 for the prevention of Staphylococcus aureus pneumonia in high-risk ICU patients

PDF

Paul Sekhri joins Topas Therapeutics as Chairman of the Board

April 04, 2017

Topas Therapeutics GmbH (Topas), a privately held biotech company pursuing a novel liver-based immune tolerance approach, today announced the election of Paul Sekhri as Chairman of the Board effective immediately.

PDF

Crescendo Biologics Appoints Philip Bland-Ward as Chief Scientific Officer

April 04, 2017
PDF

Arsanis and Adimab Enter Into License Agreement

February 27, 2017
PDF

Arsanis Announces First Patient Dosed in Global Phase 2 Study

January 24, 2017
PDF

Crescendo partners with Genedata

January 10, 2017
PDF

Luxendo announces Series A extension

January 09, 2017
PDF

Opsona announces preliminary MDS results

December 20, 2016
PDF

Opsona receives orphan designation

October 25, 2016
PDF

Crescendo enters a collaboration with Takeda

October 10, 2016
PDF

ViraT enters collaboration with Boehringer Ingelheim

September 28, 2016
PDF

Crescendo strengthens IP portfolio

September 27, 2016
PDF

Topas Series A Financing

March 22, 2016
PDF
© EMBL Ventures 2017